U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula 2C11H17NO3.H2O4S
Molecular Weight 520.594
Optical Activity ( + / - )
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ISOPROTERENOL SULFATE ANHYDROUS

SMILES

OS(O)(=O)=O.CC(C)NCC(O)C1=CC=C(O)C(O)=C1.CC(C)NCC(O)C2=CC=C(O)C(O)=C2

InChI

InChIKey=ZOLBALGTFCCTJF-UHFFFAOYSA-N
InChI=1S/2C11H17NO3.H2O4S/c2*1-7(2)12-6-11(15)8-3-4-9(13)10(14)5-8;1-5(2,3)4/h2*3-5,7,11-15H,6H2,1-2H3;(H2,1,2,3,4)

HIDE SMILES / InChI

Molecular Formula C11H17NO3
Molecular Weight 211.2576
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula H2O4S
Molecular Weight 98.078
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.drugs.com/cdi/isoproterenol.html | https://www.ncbi.nlm.nih.gov/pubmed/209581 | https://www.ncbi.nlm.nih.gov/pubmed/22073124 | https://www.ncbi.nlm.nih.gov/pubmed/11723224

Isoproterenol (trade names Medihaler-Iso and Isuprel) is a medication used for the treatment of bradycardia (slow heart rate), heart block, and rarely for asthma. Isoproterenol is a non-selective β adrenoreceptor agonist and TAAR1 agonist that is the isopropylaminomethyl analog of epinephrine. Isoprenaline's effects on the cardiovascular system (non-selective) relate to its actions on cardiac β1 receptors and β2 receptors on smooth muscle within the tunica media of arterioles. Isoprenaline has positive inotropic and chronotropic effects on the heart. β2 adrenoceptor stimulation in arteriolar smooth muscle induces vasodilation. Its inotropic and chronotropic effects elevate systolic blood pressure, while its vasodilatory effects tend to lower diastolic blood pressure. The overall effect is to decrease mean arterial pressure due to the β2 receptors' vasodilation. The adverse effects of isoprenaline are also related to the drug's cardiovascular effects. Isoprenaline can produce tachycardia (an elevated heart rate), which predisposes patients to cardiac arrhythmias.

Originator

Sources: Archiv fuer Experimentelle Pathologie und Pharmakologie, Volume 197, Pages 41-56, Journal, 1940

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ISOPROTERENOL HYDROCHLORIDE

Approved Use

Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.)

Launch Date

-4.35974406E11
Primary
ISOPROTERENOL HYDROCHLORIDE

Approved Use

Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.)

Launch Date

-4.35974406E11
Primary
ISOPROTERENOL HYDROCHLORIDE

Approved Use

Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.)

Launch Date

-4.35974406E11
Primary
ISOPROTERENOL HYDROCHLORIDE

Approved Use

Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.)

Launch Date

-4.35974406E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
42 ng/mL
0.3 mg/kg single, subcutaneous
dose: 0.3 mg/kg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
ISOPROTERENOL plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
15 mg 1 times / day multiple, respiratory (max)
Studied dose
Dose: 15 mg, 1 times / day
Route: respiratory
Route: multiple
Dose: 15 mg, 1 times / day
Sources: Page: p.642
unhealthy, 27 - 67
n = 12
Health Status: unhealthy
Condition: Bronchial asthma
Age Group: 27 - 67
Sex: M+F
Population Size: 12
Sources: Page: p.642
Other AEs: Tachycardia, Premature ventricular contractions...
Other AEs:
Tachycardia (66.7%)
Premature ventricular contractions (8.3%)
Sources: Page: p.642
0.2 mg multiple, intravenous (max)
Recommended
Dose: 0.2 mg
Route: intravenous
Route: multiple
Dose: 0.2 mg
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Heart block|Adams-Stokes attacks|Cardiac arrest
Sources: Page: p.2
Disc. AE: Block heart, Adams-Stokes syndrome...
AEs leading to
discontinuation/dose reduction:
Block heart
Adams-Stokes syndrome
Sources: Page: p.2
1 mg multiple, intramuscular (max)
Recommended
Dose: 1 mg
Route: intramuscular
Route: multiple
Dose: 1 mg
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Heart block|Adams-Stokes attacks|Cardiac arrest
Sources: Page: p.2
Disc. AE: Block heart, Adams-Stokes syndrome...
AEs leading to
discontinuation/dose reduction:
Block heart
Adams-Stokes syndrome
Sources: Page: p.2
AEs

AEs

AESignificanceDosePopulation
Tachycardia 66.7%
15 mg 1 times / day multiple, respiratory (max)
Studied dose
Dose: 15 mg, 1 times / day
Route: respiratory
Route: multiple
Dose: 15 mg, 1 times / day
Sources: Page: p.642
unhealthy, 27 - 67
n = 12
Health Status: unhealthy
Condition: Bronchial asthma
Age Group: 27 - 67
Sex: M+F
Population Size: 12
Sources: Page: p.642
Premature ventricular contractions 8.3%
15 mg 1 times / day multiple, respiratory (max)
Studied dose
Dose: 15 mg, 1 times / day
Route: respiratory
Route: multiple
Dose: 15 mg, 1 times / day
Sources: Page: p.642
unhealthy, 27 - 67
n = 12
Health Status: unhealthy
Condition: Bronchial asthma
Age Group: 27 - 67
Sex: M+F
Population Size: 12
Sources: Page: p.642
Adams-Stokes syndrome Disc. AE
0.2 mg multiple, intravenous (max)
Recommended
Dose: 0.2 mg
Route: intravenous
Route: multiple
Dose: 0.2 mg
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Heart block|Adams-Stokes attacks|Cardiac arrest
Sources: Page: p.2
Block heart Disc. AE
0.2 mg multiple, intravenous (max)
Recommended
Dose: 0.2 mg
Route: intravenous
Route: multiple
Dose: 0.2 mg
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Heart block|Adams-Stokes attacks|Cardiac arrest
Sources: Page: p.2
Adams-Stokes syndrome Disc. AE
1 mg multiple, intramuscular (max)
Recommended
Dose: 1 mg
Route: intramuscular
Route: multiple
Dose: 1 mg
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Heart block|Adams-Stokes attacks|Cardiac arrest
Sources: Page: p.2
Block heart Disc. AE
1 mg multiple, intramuscular (max)
Recommended
Dose: 1 mg
Route: intramuscular
Route: multiple
Dose: 1 mg
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Heart block|Adams-Stokes attacks|Cardiac arrest
Sources: Page: p.2
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
[Myocardial DNA and cell count following isoproterenol-induced myocardial necrosis in the rat].
1975
Method for the production of severe ventricular dysrhythmias in small laboratory animals.
1975
Metabolic response after isoproterenol-induced myocardial infarction in arteriosclerotic breeder vs nonarteriosclerotic virgin intact and gonadectomized male rats.
1975 Apr
[Pharmacology of acebutolol in animals].
1975 Dec 31
Prolyl hydroxylase and collagen metabolism after experimental mycardial infarction.
1975 Jan
Frequency of isoproterenol hydrochloride-induced cardiac arrhythmia in 19 patients with chronic obstructive pulmonary disease: a prospective study.
1975 Jun
The use of practolol in supraventricular arrhythmias associated with acute illnesses.
1975 May
Metabolic responses following isoproterenol-induced myocardial infarction in arteriosclerotic breeder vs. non-arteriosclerotic virgin and ovariectomized female rats.
1975 May-Jun
Inhibition of adipocyte lipolysis by papaverine: papaverine can inhibit the redistribution of hormone-sensitive lipase.
2000
Influences of catecholamines on the sudden death induced in dogs by an antifungal agent, D0870.
2000 Apr
Images in cardiovascular medicine. Labile repolarization from "cell to bedside".
2000 Aug 15
beta-adrenergic stimulation restores rat lung ability to clear edema in ventilator-associated lung injury.
2000 Jul
The influence of indomethacin on the acth secretion induced by central stimulation of adrenergic receptors.
2000 Jun
Requirement of activation of the extracellular signal-regulated kinase cascade in myocardial cell hypertrophy.
2000 Jun
Isoproterenol-induced myocardial injury resulting in altered S100A4 and S100A11 protein expression in the rat.
2000 Jun
Hypersensitivity of cerebral artery response to catecholamine in patients with neurally mediated syncope induced by isoproterenol.
2000 Jun 1
Mitochondrial oligomycin-sensitive ATPase during isoproterenol-induced cell injury of myocardium.
2000 Mar-Apr
Isoproterenol-induced hypertrophy may result in distinct left ventricular changes.
2000 May-Jun
[Effects of isoprenaline on apoptosis related gene expression in rat myocardium cells].
2000 Nov
Coronary microvascular endothelial cells cosecrete angiotensin II and endothelin-1 via a regulated pathway.
2000 Sep
Hemodynamic and antiadrenergic effects of dronedarone and amiodarone in animals with a healed myocardial infarction.
2000 Sep
Lipopolysaccharide-induced tumor necrosis factor-alpha release is controlled by the central nervous system.
2001
Evidence that ranolazine behaves as a weak beta1- and beta2-adrenoceptor antagonist in the rat [correction of cat] cardiovascular system.
2001 Apr
Elevated parasympathetic nerve tone in isoproterenol-induced neurally mediated syncope during head-up tilt testing.
2001 Apr
Effects of alpha- and beta-adrenergic stimulation on free magnesium concentrations in platelets from healthy and obese individuals.
2001 Dec
Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac renin-angiotensin system.
2001 Dec
Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase.
2001 Feb
Paroxysmal tachycardia in children and teenagers with normal sinus rhythm and without heart disease.
2001 Jan
Interaction of calcitonin gene-related peptide (CGRP), substance P (SP) and conventional autonomic agonists in rat submandibular salivary peroxidase release in vitro.
2001 Jan 14
cAMP mediated upregulation of CYP2A5 in mouse hepatocytes.
2001 Jan 26
Activation of mitochondrial oxidative phosphorylation during (+/-)-isoproterenol-induced cell injury of myocardium.
2001 Jan-Mar
[Functional characterization of myocardial hypertrophy induced by isoproterenol and its regression].
2001 Jul
A new aspect of view in synthesizing new type beta-adrenoceptor blockers with ancillary antioxidant activities.
2001 Jul
Catecholamines stimulate interleukin-6 synthesis in rat cardiac fibroblasts.
2001 Jul
Alterative and plastic insufficiency of cardiomyocytes: isoproterenol-induced damage to myocardium during anthracycline cardiomyopathy.
2001 Jun
beta-Adrenergic and endothelin receptor interaction in dilated human cardiomyopathic myocardium.
2001 Jun
Report of a life-threatening arrhythmia after hospital discharge in a liver transplant recipient with previously unknown congenital long QT syndrome.
2001 Jun-Jul
In vivo regulation of Na/Ca exchanger expression by adrenergic effectors.
2001 Mar
Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo.
2001 Mar 13
Neurohormonal regulation of secretion from isolated rat stomach ECL cells: a critical reappraisal.
2001 Mar 2
Cardioprotective effects of Picrorrhiza kurroa against isoproterenol-induced myocardial stress in rats.
2001 May
PKC-beta is not necessary for cardiac hypertrophy.
2001 May
Spironolactone and captopril attenuates isoproterenol-induced cardiac remodelling in rats.
2001 Oct
Calcineurin-GATA4 pathway is involved in beta-adrenergic agonist-responsive endothelin-1 transcription in cardiac myocytes.
2001 Sep 14
Expression of human angiotensinogen-renin in rat: effects on transcription and heart function.
2002 Feb
Effect of an orally active Na+/H+ exchange inhibitor, SMP-300, on experimental angina and myocardial infarction models in rats.
2002 Feb
99mTc-glucarate for detection of isoproterenol-induced myocardial infarction in rats.
2002 Feb 21
Synergistic effect of nicorandil and amlodipine on mitochondrial function during isoproterenol-induced myocardial infarction in rats.
2002 Jan
Allosteric modulation of beta2-adrenergic receptor by Zn(2+).
2002 Jan
Glucose uptake via SGLT-1 is stimulated by beta(2)-adrenoceptors in the ruminal epithelium of sheep.
2002 Jun
Patents

Sample Use Guides

Bolus intravenous injection: 0.02 mg to 0.06 mg; Intravenous infusion: 5 mcg/min; Intramuscular 0.2 mg; Subcutaneous 0.2 mg; Intracardiac 0.02 mg;
Route of Administration: Other
Human embryonic kidney cells (HEK293) were cultured in Minimum Essential Medium (MEM) Earle’s (Biochrom AG) supplemented with 10% FBS (PAA Laboratories GmbH), 100 U/ml penicillin, and 100 mg/ml streptomycin (Biochrom AG) and 2 mM L-glutamine (Invitrogen) at 37C with 5% CO2. 48 well plates were coated with Poly-L-Lysine (Biochrom) and HEK293 cells were seeded with 37,500 cells per well. Transient transfection in triplicates with 84 ng DNA/well using metafectene according to manufactures instructions (Biontex, Munich, Germany) was performed 28 hours later. 40 hours after transfection cells were pre-incubated for 5 minutes with stimulation buffer containing of MEM Earle’s media and 1 mM 3-isobutyl-1-methylxanthine (IBMX, Sigma). This stimulation buffer was used for all further steps. For ligand competition experiments cells were incubated with tyramine, 2-phenylethylamine or octopamine ranging from 6.7 nM to 6700 nM, diluted in stimulation buffer for 15 minutes followed by a stimulation with isoprenaline in concentrations ranging from 1 nM to 10000 nM for 30 minutes. All reactions were performed at 37C with 5% CO2 saturated air and stopped by aspirating medium.
Substance Class Chemical
Created
by admin
on Fri Dec 16 20:24:47 UTC 2022
Edited
by admin
on Fri Dec 16 20:24:47 UTC 2022
Record UNII
052RYF6JDD
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ISOPROTERENOL SULFATE ANHYDROUS
Common Name English
Isoprenaline sulfate [WHO-DD]
Common Name English
1,2-BENZENEDIOL, 4-(1-HYDROXY-2-((1-METHYLETHYL)AMINO)ETHYL)-, SULFATE (2:1)
Systematic Name English
Code System Code Type Description
FDA UNII
052RYF6JDD
Created by admin on Fri Dec 16 20:24:47 UTC 2022 , Edited by admin on Fri Dec 16 20:24:47 UTC 2022
PRIMARY
PUBCHEM
8239
Created by admin on Fri Dec 16 20:24:47 UTC 2022 , Edited by admin on Fri Dec 16 20:24:47 UTC 2022
PRIMARY
ECHA (EC/EINECS)
206-085-2
Created by admin on Fri Dec 16 20:24:47 UTC 2022 , Edited by admin on Fri Dec 16 20:24:47 UTC 2022
PRIMARY
EPA CompTox
DTXSID60985824
Created by admin on Fri Dec 16 20:24:47 UTC 2022 , Edited by admin on Fri Dec 16 20:24:47 UTC 2022
PRIMARY
CAS
299-95-6
Created by admin on Fri Dec 16 20:24:47 UTC 2022 , Edited by admin on Fri Dec 16 20:24:47 UTC 2022
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY